Skip to main content

TScan Therapeutics, Inc.

TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001783328

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.6M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by TScan Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for TScan Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for TScan Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Baker JulianDirector2,528,583IndirectMay 22, 20261
Baker FelixDirector2,528,583IndirectMay 22, 20261
Baker Bros. Advisors LPDirector2,528,583IndirectMay 22, 20261
Baker Brothers Life Sciences LPDirector2,528,583IndirectMay 22, 20261
667, L.P.Director2,528,583IndirectMay 22, 20261
Baker Bros. Advisors (GP) LLCDirector2,528,583IndirectMay 22, 20261
Dorton KatinaDirector–May 22, 20261
Nicholson Garry ADirector–May 22, 20261
Klencke BarbaraDirector45,000May 22, 20261
Gruia GabrielaDirector–May 22, 20261
Woods KeithDirector–May 22, 20261
Amello JasonChief Financial Officer–Jan 22, 20261
MacBeath GavinChief Executive Officer49,767Jan 22, 20261
Zdraveski ZoranSee Remarks4,716Jan 22, 20261
Dworak LeidenSee Remarks–Jan 22, 20261
Louis ChrystalChief Medical Officer–Jan 22, 20261
Nichols Weston10% Owner8,019,148IndirectDec 23, 20251
Lynx1 Capital Management LP10% Owner8,019,148IndirectDec 23, 20251
Barberich Timothy JDirector67,027Dec 21, 20230
Silver Brian M.Chief Financial Officer32,885Jun 15, 20230
Barton DeboraChief Medical Officer–Jun 15, 20230
Southwell David PChief Executive Officer171,569Feb 6, 20230
Desmarais WilliamChief Business Officer2,500Jul 27, 20220
Harel IttaiDirector–Jun 3, 20220
Westphal Christoph H10% Owner1,278,838IndirectJul 22, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 23, 2025 (view filing)6:17 PM ETDec 194 daysNichols Weston and 1 other10% OwnerPPurchaseCommon stock, $0.0001 par value per share ("Common Stock")+80.1K$0.8989+$72.0K+1.0%7.94M after
Dec 23, 2025 (view filing)6:17 PM ETDec 22-231 dayNichols Weston and 1 other10% OwnerPPurchase+81.7K$0.8999+$73.6K+1.0%8.02M after2 lots
May 21, 2025 (view filing)4:49 PM ETMay 192 daysNichols Weston and 1 other10% OwnerPPurchaseCommon stock, $0.0001 par value per share ("Common Stock")+1.39M$1.20+$1.67M+25.9%6.75M after
May 21, 2025 (view filing)4:49 PM ETMay 201 dayNichols Weston and 1 other10% OwnerPPurchase+1.20M$1.20+$1.44M+17.8%7.95M after
Dec 30, 2024 (view filing)4:15 PM ETDec 264 daysNichols Weston and 1 other10% OwnerPPurchase+7.50M$4.00+$30.0M–7.50M afterDerivative
Dec 16, 2024 (view filing)4:26 PM ETDec 124 daysNichols Weston and 1 other10% OwnerPPurchaseCommon stock, $0.0001 par value per share ("Common Stock")+31.8K$3.01+$95.6K+0.6%5.26M after
Dec 16, 2024 (view filing)4:26 PM ETDec 133 daysNichols Weston and 1 other10% OwnerPPurchase+100.0K$2.90+$290.1K+1.9%5.36M after
Nov 19, 2024 (view filing)4:26 PM ETNov 154 daysNichols Weston and 1 other10% OwnerPPurchaseCommon stock, $0.0001 par value per share+947$4.34+$4.11K0.0%5.23M after
Sep 24, 2024 (view filing)Sep 231 dayKlencke BarbaraDirectorPPurchaseVoting Common Stock+5.00K$5.29+$26.4K+12.5%45.0K after
Aug 27, 2024 (view filing)Aug 23-264 daysKlencke BarbaraDirectorPPurchaseVoting Common Stock+10.0K$5.61+$56.1K+33.3%40.0K after2 lots
Aug 27, 2024 (view filing)Aug 234 daysZdraveski ZoranSee RemarksSSaleVoting Common Stock−164.7K$5.78−$951.9K−97.2%4.72K after
Apr 23, 2024 (view filing)4:17 PM ETApr 194 daysBaker Julian and 5 othersDirectorPPurchase+9.68M$7.13+$69.0M–43.2M afterDerivative2 lots
Apr 23, 2024 (view filing)4:15 PM ETApr 194 daysNichols Weston and 1 other10% OwnerPPurchase+5.00M$7.13+$35.6M–5.00M afterDerivative
Dec 21, 2023 (view filing)Dec 18-193 daysLateBarberich Timothy JDirectorPPurchaseVoting Common Stock+29.1K$4.89+$142.6K+76.9%67.0K after2 lots
Dec 18, 2023 (view filing)Dec 144 daysKlencke BarbaraDirectorPPurchaseVoting Common Stock+5.00K$5.08+$25.4K+20.0%30.0K after
Jun 6, 2023 (view filing)Jun 24 daysBarberich Timothy JDirectorPPurchaseVoting Common Stock+37.9K$2.63+$99.6KNew position37.9K after
Jun 2, 2023 (view filing)5:35 PM ETMay 312 daysNichols Weston and 1 other10% OwnerSSaleCommon stock, $0.0001 par value per share Common Stock−10.0K$2.51−$25.1K−0.2%5.24M after
Jun 2, 2023 (view filing)5:35 PM ETMay 312 daysNichols Weston and 1 other10% OwnerSSale−15.4K$2.52−$38.8K−0.3%5.22M after2 lots
Dec 29, 2022 (view filing)Dec 27-282 daysSilver Brian M.Chief Financial OfficerPPurchaseVoting Common Stock+6.00K$1.53+$9.19K+22.3%32.9K after2 lots
May 20, 2022 (view filing)May 182 daysSouthwell David PChief Executive OfficerPPurchaseVoting Common Stock+25.0K$3.59+$89.8K+17.1%171.6K after2 lots
May 12, 2022 (view filing)4:41 PM ETMay 10-112 daysBaker Julian and 5 othersDirector, 10% OwnerPPurchase+1.36M$1.88+$2.56M+116.3%2.53M after8 lots
Mar 28, 2022 (view filing)Mar 244 daysSilver Brian M.Chief Financial OfficerPPurchaseVoting Common Stock+15.0K$3.40+$51.0K+126.2%26.9K after
Sep 27, 2021 (view filing)Sep 234 daysZdraveski ZoranChief Legal OfficerPPurchaseVoting Common Stock+4.72K$7.48+$35.3KNew position4.72K after
Sep 22, 2021 (view filing)Sep 211 daySilver Brian M.Chief Financial OfficerPPurchaseVoting Common Stock+5.00K$6.32+$31.6K+72.6%11.9K after
Sep 22, 2021 (view filing)Sep 20-212 daysMacBeath GavinChief Scientific OfficerPPurchaseVoting Common Stock+5.00K$6.22+$31.1K+11.2%49.8K after2 lots
Sep 13, 2021 (view filing)Sep 94 daysSilver Brian M.Chief Financial OfficerPPurchaseVoting Common Stock+5.88K$8.48+$49.9K+588.5%6.88K after
Sep 9, 2021 (view filing)Sep 81 daySouthwell David PChief Executive OfficerPPurchaseVoting Common Stock+11.0K$8.73+$96.0K+12.7%97.9K after
Aug 31, 2021 (view filing)Aug 274 daysDesmarais WilliamChief Business OfficerPPurchaseVoting Common Stock+2.50K$9.08+$22.7KNew position2.50K after
Jul 22, 2021 (view filing)4:06 PM ETJul 202 daysBaker Julian and 5 othersDirectorPPurchase+1.43M$15.00+$21.4MNew position1.32M after2 lots
Jul 22, 2021 (view filing)Jul 202 daysWestphal Christoph H10% OwnerPPurchaseVoting Common Stock+133.3K$15.00+$2.00M+11.6%1.28M after
Jul 22, 2021 (view filing)Jul 202 daysSilver Brian M.Chief Financial OfficerPPurchaseVoting Common Stock+1.00K$15.00+$15.0KNew position1.00K after